Traitements de 2e et 3e ligne : chimiothérapie ou TKI de l'EGFR ?

The analysis of all studies on the subject does not pinpoint any molecules that should be preferred above the others in terms of effectiveness, but there are many factors to consider: the histological type, the treatment used in the first line and maintenance therapy, the administration route, the tolerance profile which differs greatly for each of these 3 molecules, comorbidities and whether the patient is an active smoker or not. Finally, we must take other mutations into account: therefore, we prefer crizotinib in the event of ALK rearrangement and we would avoid giving an EGFR TKI in the event of a Kras mutation if possible.